Despite China notably accelerating new drug reviews and approvals, the government is giving priority to domestically developed innovative drugs, causing many foreign companies to cry foul of an uneven playground, a newly released business climate survey shows.
The survey, conducted in February of its 538 member companies by the EU Chamber of Commerce in China (EUCCC), was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?